US FDA approves AstraZeneca Imfinzi and Padcev combination therapy for muscle-invasive bladder cancer
AZN Astrazeneca plc
$178.76 -1.93%
View chart & analysis → - 1The US Food and Drug Administration (FDA) has approved the combination therapy of Imfinzi and Padcev for adult patients with muscle-invasive bladder cancer who have not received or have refused cisplatin-based chemotherapy.
- 2The VOLGA clinical trial confirmed a 49% reduction in the risk of disease progression, recurrence, surgery omission, or death compared to radical bladder resection, regardless of whether approved adjuvant therapy was used.
- 3The therapy recorded a 2-year event-free survival rate of 64% compared to 45% for the control group.
So what's the key point?
A new treatment method using two of AstraZeneca's drugs together to treat bladder cancer has been approved in the US. This treatment was confirmed to reduce the risk of disease worsening or death by 49%.
Source Pharmaceutical Business Review +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.